218153-01-6

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 6399-81-1 triphenylphosphine hydrobromide 
• 899350-32-4 4-(3-bromophenyl)-butyric acid 
• 823-78-9 meta-bromobenzyl bromide 
• 161173-98-4 1-bromo-3-(but-3-en-1-yl)benzene 
• 54887-20-6 1-bromo-3-n-butylbenzene 

Downstream Products

• 620600-91-1 [4-(3-bromophenyl)butoxy](tert-butyl)diphenylsilane 
• 853643-74-0 1-bromo-3-(4-methoxy-butyl)-benzene 
• 931430-07-8 Toluene-4-sulfonic acid 4-(3-bromo-phenyl)butyl ester 
• 109757-62-2 1-bromo-3-(4-bromobutyl)benzene 
• 1426943-39-6 2-(4-(3-bromophenyl)butyl)isoindoline-1,3-dione 

Relevant academic research and scientific papers

Enantioselective Intermolecular C-H Amination Directed by a Chiral Cation

The enantioselective amination of C(sp3)-H bonds is a powerful synthetic transformation yet highly challenging to achieve in an intermolecular sense. We have developed a family of anionic variants of the best-in-class catalyst for Rh-catalyzed C-H amination, Rh2(esp)2, with which we have associated chiral cations derived from quaternized cinchona alkaloids. These ion-paired catalysts enable high levels of enantioselectivity to be achieved in the benzylic C-H amination of substrates bearing pendant hydroxyl groups. Additionally, the quinoline of the chiral cation appears to engage in axial ligation to the rhodium complex, providing improved yields of product versus Rh2(esp)2 and highlighting the dual role that the cation is playing. These results underline the potential of using chiral cations to control enantioselectivity in challenging transition-metal-catalyzed transformations.

MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules,

A modular synthesis of teraryl-based α-helix mimetics, part 1: Synthesis of core fragments with two electronically differentiated leaving groups

Teraryl-based α-helix mimetics have proven to be useful compounds for the inhibition of protein-protein interactions (PPI). We have developed a modular and flexible approach for the synthesis of teraryl-based α-helix mimetics. Central to our strategy is the use of a benzene core unit featuring two leaving groups of differentiated reactivity in the Pd-catalyzed cross-coupling used for terphenyl assembly. With the halogen/diazonium route and the halogen/triflate route, two strategies have successfully been established. The synthesis of core building blocks with aliphatic (Ala, Val, Leu, Ile), aromatic (Phe), polar (Cys, Lys), hydrophilic (Ser, Gln), and acidic (Glu) amino acid side chains are reported. Turn on: Teraryl-based α-helix mimetics can be effectively produced by sequential Suzuki coupling of a central core fragment featuring electronically differentiated leaving groups with aryl boronic pinacol esters (see scheme; dppf=1,1′-bis(diphenylphosphino) ferrocene, DME=dimethoxyethane, Pin=pinacol, Tf=trifluoromethanesulfonyl). With a set of only 2×18 building blocks, all permutations of α-helix mimetics can be produced. Copyright

AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE

The present invention provides compounds and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

AMINO-5-[4-(DIFLUOROMETHOXY)-PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE

The present invention provides a 2-amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

Triazolo-1,4-diazepine compounds and medicinal composition containing the same

A triazolo-1,4-diazepine compound having the formula (I): wherein A represents CO, CO—B, or B, B represents a C1to C6alkylene group or a C2to C6alkylene group having an oxygen atom interposed in the middle thereof, X represents N—O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1to C6lower alkyloxy group or a C1to C6lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1represents a hydrogen atom or a C1to C3lower alkyl group having both a PAF antagonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.